A recent trial has revealed that amivantamab, an injection developed by Johnson & Johnson, can effectively eliminate tumors in some patients with head and neck cancer. Out of 102 participants across 11 countries, over one-third experienced a reduction in tumor size, with 28 patients showing significant shrinkage, and 15 achieving complete tumor dissolution. Remarkably, changes were observed in less than a week. This treatment is particularly aimed at patients whose cancer has not responded to other therapies. Those who received the injection had a median survival of one year, despite the challenging prognosis typically associated with this cancer type. Amivantamab operates through three mechanisms: blocking epidermal growth factor receptors, hindering the MET pathway, and stimulating the immune system to target tumors. Experts, including Kevin Harrington from London's Institute of Cancer Research, have highlighted the unprecedented responses observed, noting the potential for this treatment to help thousands of patients each year.